×

Message

Sorry - this event cannot be viewed using the link provided. Its possible the item may have been updated while you have been viewing the webpage.

Supernus Pharmaceuticals.png

Supernus Pharmaceuticals Inc. capped off its first week on the Nasdaq up nearly $1 from its initial public offering price. With its IPO in the bag, the Rockville biotech now turns to a bigger gamble: seeing two drugs through Food and Drug Administration approval and onto the commercial market.

The modestly successful May 1 offering marks the first time a Washington-area biotech has gone public since 2007 and leaves Supernus with a pile of cash to shovel into its lead product candidates — epilepsy drugs SPN-538 and SPN-804.

To read the full, original article click on this link: Supernus moves from IPO to FDA - Washington Business Journal